loading
전일 마감가:
$46.29
열려 있는:
$46.37
하루 거래량:
1.49M
Relative Volume:
1.17
시가총액:
$4.09B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-10.71
EPS:
-4.47
순현금흐름:
$-191.20M
1주 성능:
+1.33%
1개월 성능:
-0.33%
6개월 성능:
-15.70%
1년 성능:
-32.08%
1일 변동 폭
Value
$45.85
$48.00
1주일 범위
Value
$45.51
$48.28
52주 변동 폭
Value
$43.42
$91.10

크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile

Name
명칭
Crispr Therapeutics Ag
Name
전화
(617) 315-4600
Name
주소
BAARERSTRASSE 14, ZUG
Name
직원
407
Name
트위터
@crisprtx
Name
다음 수익 날짜
2024-12-05
Name
최신 SEC 제출 서류
Name
CRSP's Discussions on Twitter

CRSP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
CRSP 47.88 4.09B 170.10M -239.59M -191.20M -4.47
VRTX 450.97 116.38B 10.63B -479.80M -1.35B 13.33
REGN 738.00 82.09B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.14B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.25B 3.30B -501.07M 1.03B 11.54

크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-02-15 개시 Wolfe Research Peer Perform
2023-12-11 다운그레이드 TD Cowen Market Perform → Underperform
2023-10-17 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-09-27 개시 Mizuho Buy
2023-08-17 업그레이드 Citigroup Neutral → Buy
2023-05-30 개시 William Blair Outperform
2023-04-13 개시 Cantor Fitzgerald Overweight
2023-03-21 개시 Bernstein Mkt Perform
2023-03-17 개시 Bryan Garnier Buy
2023-03-07 개시 Robert W. Baird Neutral
2022-10-11 개시 Morgan Stanley Underweight
2022-08-09 다운그레이드 Barclays Overweight → Equal Weight
2022-06-23 다운그레이드 Evercore ISI Outperform → In-line
2022-06-17 개시 BMO Capital Markets Outperform
2022-04-28 개시 Credit Suisse Neutral
2021-12-07 개시 Cowen Market Perform
2021-10-19 개시 SVB Leerink Outperform
2021-06-14 업그레이드 Citigroup Sell → Neutral
2021-04-21 업그레이드 Jefferies Hold → Buy
2021-03-04 개시 JMP Securities Mkt Outperform
2020-12-10 재확인 Chardan Capital Markets Buy
2020-12-10 다운그레이드 Jefferies Buy → Hold
2020-12-10 재확인 Needham Buy
2020-12-07 다운그레이드 Wells Fargo Overweight → Equal Weight
2020-10-23 개시 RBC Capital Mkts Sector Perform
2020-10-05 개시 BofA Securities Buy
2020-07-28 재확인 Needham Buy
2020-07-14 개시 SunTrust Buy
2020-06-15 재확인 Canaccord Genuity Buy
2020-03-05 개시 Stifel Hold
2020-02-03 다운그레이드 Evercore ISI Outperform → In-line
2019-11-19 업그레이드 William Blair Mkt Perform → Outperform
2019-11-12 업그레이드 Oppenheimer Perform → Outperform
2019-08-01 개시 Jefferies Buy
2019-07-26 개시 Canaccord Genuity Buy
2019-06-10 개시 ROTH Capital Buy
2019-04-12 개시 Evercore ISI Outperform
2019-03-14 개시 William Blair Mkt Perform
2019-01-28 다운그레이드 Goldman Buy → Neutral
2019-01-22 다운그레이드 Citigroup Neutral → Sell
모두보기

크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스

pulisher
Nov 22, 2024

Learn to Evaluate (CRSP) using the Charts - Stock Traders Daily

Nov 22, 2024
pulisher
Nov 21, 2024

Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey

Nov 21, 2024
pulisher
Nov 20, 2024

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? - Yahoo Finance

Nov 20, 2024
pulisher
Nov 19, 2024

The Best Biotech Stocks to Buy - Morningstar

Nov 19, 2024
pulisher
Nov 19, 2024

CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance

Nov 19, 2024
pulisher
Nov 19, 2024

10 Best Genomics Stocks To Buy Right Now - Insider Monkey

Nov 19, 2024
pulisher
Nov 19, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Large Increase in Short Interest - MarketBeat

Nov 19, 2024
pulisher
Nov 17, 2024

CRISPR Therapeutics AG (CRSP): Among ARK Invest’s Top Stock Picks for 2024 - Insider Monkey

Nov 17, 2024
pulisher
Nov 17, 2024

Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool

Nov 17, 2024
pulisher
Nov 16, 2024

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More - Yahoo Finance

Nov 16, 2024
pulisher
Nov 15, 2024

Gene Editing Tools Market Size, Growth Opportunities, - openPR

Nov 15, 2024
pulisher
Nov 15, 2024

First Week of July 2025 Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq

Nov 15, 2024
pulisher
Nov 14, 2024

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Van ECK Associates Corp Sells 78,228 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million By Investing.com - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Sumitomo Mitsui Trust Group Inc. Has $139.44 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Baillie Gifford & Co. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

CRISPR Therapeutics (CRSP) Stock Analysis: An Unexpected Rise Amidst A Flat Market - Barchart

Nov 13, 2024
pulisher
Nov 12, 2024

CRISPR Therapeutics' SWOT analysis: gene editing pioneer faces casgevy launch challenges - Investing.com India

Nov 12, 2024
pulisher
Nov 11, 2024

Crispr Therapeutics Q3 EarningsNo Casgevy Revenue, But Plenty Of Optimism (NASDAQ:CRSP) - Seeking Alpha

Nov 11, 2024
pulisher
Nov 11, 2024

(CRSP) Investment Analysis - Stock Traders Daily

Nov 11, 2024
pulisher
Nov 11, 2024

What is Chardan Capital's Estimate for CRSP FY2024 Earnings? - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 09, 2024
pulisher
Nov 08, 2024

What is Leerink Partnrs' Forecast for CRSP FY2024 Earnings? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by ARK Investment Management LLC - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

CRSP FY2024 EPS Reduced by Brookline Capital Management - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates - MSN

Nov 08, 2024
pulisher
Nov 07, 2024

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Positive Long-Term Outlook for Crispr Driven by Casgevy and Diverse Gene Editing Portfolio - Morningstar

Nov 06, 2024
pulisher
Nov 06, 2024

Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High? - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

CRISPR Therapeutics Sell rating reiterated on recent performance - Investing.com

Nov 06, 2024
pulisher
Nov 06, 2024

Barclays Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform By Investing.com - Investing.com Canada

Nov 06, 2024
pulisher
Nov 06, 2024

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

Crispr Therapeutics earnings beat by $0.41, revenue fell short of estimates - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4%Time to Sell? - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

CRSPCRISPR Therapeutics AG Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

CRISPR Q3: CASGEVY Expands Global Reach, $1.9B Cash Position as Losses Narrow | CRSP Stock News - StockTitan

Nov 05, 2024

크리스퍼 테라퓨틱스 (CRSP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):